Humans; Transcription Factor RelA/genetics/metabolism; Tumor Necrosis Factor-alpha/metabolism; NF-kappa B/metabolism; Active Transport, Cell Nucleus; Inflammation/genetics/metabolism; Epithelial Cells/metabolism; NF-κB; gingival; oral epithelium; oral inflammation; p65; periodontitis; resolvin; specialized pro-resolving mediators
[en] Specialized pro-resolving mediators (SPMs) are multifunctional lipid mediators that participate in the resolution of inflammation. We have recently described that oral epithelial cells (OECs) express receptors of the SPM resolvin RvD1(n-3 DPA) and that cultured OECs respond to RvD1(n-3 DPA) addition by intracellular calcium release, nuclear receptor translocation and transcription of genes coding for antimicrobial peptides. The aim of the present study was to assess the functional outcome of RvD1(n-3 DPA)-signaling in OECs under inflammatory conditions. To this end, we performed transcriptomic analyses of TNF-α-stimulated cells that were subsequently treated with RvD1(n-3 DPA) and found significant downregulation of pro-inflammatory nuclear factor kappa B (NF-κB) target genes. Further bioinformatics analyses showed that RvD1(n-3 DPA) inhibited the expression of several genes involved in the NF-κB activation pathway. Confocal microscopy revealed that addition of RvD1(n-3 DPA) to OECs reversed TNF-α-induced nuclear translocation of NF-κB p65. Co-treatment of the cells with the exportin 1 inhibitor leptomycin B indicated that RvD1(n-3 DPA) increases nuclear export of p65. Taken together, our observations suggest that SPMs also have the potential to be used as a therapeutic aid when inflammation is established.
Human health sciences: Multidisciplinary, general & others
Life sciences: Multidisciplinary, general & others